Warburg Pincus and ArchiMed Invest in Polyplus-transfection

April 29, 2020

Warburg Pincus has made a major growth investment in Polyplus-transfection SA alongside existing majority shareholder ArchiMed, with both firms becoming equal shareholders while Polyplus management remains significant minority owners. The capital will be used to expand production capacity, accelerate product innovation, increase international expansion, and hire across technical, regulatory, and commercial functions to serve the gene and cell therapy market.

Buyers
Warburg Pincus, ArchiMed (ARCHIMED)
Targets
Polyplus-transfection SA
Industry
Biotechnology
Location
Grand Est, France
Transaction Type
Growth capital

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.